Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges
- 2 June 2020
- journal article
- review article
- Published by Informa UK Limited in Emerging Therapeutic Targets
- Vol. 24 (6), 545-558
- https://doi.org/10.1080/14728222.2020.1751820
Abstract
Introduction: Nasopharyngeal carcinoma (NPC) is a major public health problem in several countries, especially those in Southeast Asia and North Africa. In its typical poorly differentiated form, the Epstein-Barr virus (EBV) genome is present in the nuclei of all malignant cells with restricted expression of a few viral genes. The malignant phenotype of NPC cells results from the influence of these viral products in combination with cellular genetic, epigenetic and functional alterations. With regard to host/tumor interactions, NPC is a remarkable example of immune escape in the context of a hot tumor. Areas covered: This article has an emphasis on emerging therapeutic targets that are considered upstream or at an early stage of clinical application. It examines targets related to cellular oncogenic alterations, latent EBV infection and tumor interactions with the immune system. Expert opinion: There is a remarkable emergence of new agents that target EBV products. The clinical application of these agents would benefit from a systematic and comprehensive molecular classification of NPCs and from easy access to pre-clinical models in public repositories. There is a strong rationale for more investigations on the potential of immune modulators, especially those related to NK cells.Keywords
Funding Information
- the Bristol-Myers-Squibb Foundation for Research on Immuno-Oncology (Grant n° 1709-04-040)
This publication has 124 references indexed in Scilit:
- Galectin-9 Functionally Impairs Natural Killer Cells in Humans and MiceJournal of Virology, 2013
- Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cellsProceedings of the National Academy of Sciences, 2012
- Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven TumorsClinical Cancer Research, 2012
- Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: Suggestion of a potential protective role of oestrogenEuropean Journal Of Cancer, 2012
- Host–tumor interactions in nasopharyngeal carcinomasSeminars in Cancer Biology, 2012
- Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC FamiliesClinical Cancer Research, 2011
- The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral ProductionJournal of Virology, 2010
- Epstein-Barr virus (EBV)–encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3The Journal of Experimental Medicine, 2009
- Induction of Epidermal Growth Factor Receptor Expression by Epstein-Barr Virus Latent Membrane Protein 1 C-Terminal-Activating Region 1 Is Mediated by NF-κB p50 Homodimer/Bcl-3 ComplexesJournal of Virology, 2007
- Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patientsBritish Journal of Cancer, 2007